Sangamo Therapeutics (SGMOQ) Operating Leases (2019 - 2025)

Sangamo Therapeutics has reported Operating Leases for 7 years, with the latest figure at $26.8 million in Q4 2025.

• On a quarterly basis, Operating Leases rose 2.06% year-over-year to $26.8 million in Q4 2025; TTM through Dec 2025 was $26.8 million, a 2.06% increase from a year earlier, with the FY2025 full-year figure at $26.8 million, up 2.06% from the prior year.
• Operating Leases was $26.8 million for Q4 2025 at Sangamo Therapeutics, up from $25.4 million in the prior quarter.
• The five-year high for Operating Leases was $44.1 million in Q4 2021, with the low at $23.5 million in Q2 2025.
• Average Operating Leases over 5 years is $34.4 million, with a median of $35.7 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2024: Operating Leases gained 14.74% in 2021, then retreated 21.67% in 2024.
• Over 5 years, Operating Leases stood at $44.1 million in 2021, then retreated by 11.51% to $39.0 million in 2022, then slipped by 14.03% to $33.5 million in 2023, then declined by 21.67% to $26.3 million in 2024, then climbed by 2.06% to $26.8 million in 2025.
• The last three Operating Leases figures came in at $26.8 million (Q4 2025), $25.4 million (Q3 2025), and $23.5 million (Q2 2025), per Business Quant data.